Other formats:
BibTeX
LaTeX
RIS
@article{1392780, author = {Zlámalíková, Lenka and Moulis, Mojmír and Ravčuková, Barbora and Lišková, Květoslava and Malčíková, Jitka and Šálek, David and Jarkovský, Jiří and Svitáková, Miluše and Hrabálková, Renata and Šmarda, Jan and Šmardová, Jana}, article_location = {ATHENS}, article_number = {4}, doi = {http://dx.doi.org/10.3892/or.2017.5891}, keywords = {mantle cell lymphoma; diffuse large B-cell lymphoma; p53 tumor suppressor; FASAY; TP53 mutation}, language = {eng}, issn = {1021-335X}, journal = {Oncology Reports}, title = {Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas}, url = {https://www.spandidos-publications.com/10.3892/or.2017.5891}, volume = {38}, year = {2017} }
TY - JOUR ID - 1392780 AU - Zlámalíková, Lenka - Moulis, Mojmír - Ravčuková, Barbora - Lišková, Květoslava - Malčíková, Jitka - Šálek, David - Jarkovský, Jiří - Svitáková, Miluše - Hrabálková, Renata - Šmarda, Jan - Šmardová, Jana PY - 2017 TI - Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas JF - Oncology Reports VL - 38 IS - 4 SP - 2535-2542 EP - 2535-2542 PB - SPANDIDOS PUBL LTD SN - 1021335X KW - mantle cell lymphoma KW - diffuse large B-cell lymphoma KW - p53 tumor suppressor KW - FASAY KW - TP53 mutation UR - https://www.spandidos-publications.com/10.3892/or.2017.5891 N2 - Mutations and deletions of the tumor suppressor TP53 gene are the most frequent genetic alterations detected in human tumors, though they are rather less frequent in lymphomas. However, acquisition of the TP53 mutation was demonstrated to be one of the characteristic markers in mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) and prognostic value of the TP53 status has been recognized for these diseases. We present the complex analysis of the TP53 aberrations in 57 cases of MCL and 131 cases of DLBCL. The TP53 status was determined by functional analyses in yeast (FASAY) followed by cDNA and gDNA sequencing. The level of the p53 protein was assessed by immunoblotting and loss of the TP53-specific locus 17p13.3 was detected by FISH. Altogether, we detected 13 TP53 mutations among MCL cases (22.8%) and 29 TP53 mutations in 26 from 131 DLBCL cases (19.8%). The ratio of missense TP53 mutations was 76.9% in MCL and 82.8% in DLBCL. The frequency of TP53 locus deletion was rather low in both diseases, reaching 9.3% in MCL and 15.3% in DLBCL. The presence of TP53 mutation was associated with shorter overall survival (OS) and progression-free survival (PFS) in MCL. Among DLBCL cases, the TP53 mutations shortened both OS and PFS of patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) and decreased both OS and PFS of patients with secondary DLBCL disease. ER -
ZLÁMALÍKOVÁ, Lenka, Mojmír MOULIS, Barbora RAVČUKOVÁ, Květoslava LIŠKOVÁ, Jitka MALČÍKOVÁ, David ŠÁLEK, Jiří JARKOVSKÝ, Miluše SVITÁKOVÁ, Renata HRABÁLKOVÁ, Jan ŠMARDA and Jana ŠMARDOVÁ. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas. \textit{Oncology Reports}. ATHENS: SPANDIDOS PUBL LTD, 2017, vol.~38, No~4, p.~2535-2542. ISSN~1021-335X. Available from: https://dx.doi.org/10.3892/or.2017.5891.
|